Madrid | Permanent | Circa €170,000 plus package, depending on experience and location

The opportunity

An innovative, clinically driven biotech is looking for a Medical Oncologist to lead early clinical development across a growing portfolio of small molecule assets in solid tumours. Several programmes are already in Phase 1 and Phase 2, with selected assets progressing towards Phase 3 and new compounds expected to enter clinical development.

The focus is Phase 1. You’ll help determine which indications and patient populations to pursue, how to structure dose escalation and expansion cohorts, and what evidence is needed to justify moving into Phase 2. You’ll also take direct medical responsibility for the studies you design, reviewing emerging data at patient level, working through clinical questions with investigators and using what you see in the trial to inform the next development decision.

Key responsibilities

• Lead the clinical development strategy for early oncology assets, defining priority indications, target patient populations and the evidence needed to advance each programme

• Design Phase 1 and Phase 2 trials and lead protocol development, including dose escalation, cohort expansion, eligibility criteria and endpoint selection

• Provide hands-on medical oversight of active studies, reviewing individual patient data and assessing emerging safety, tolerability and preliminary signs of antitumour activity

• Guide decisions on dose escalation, expansion cohorts and Phase 2 study design as clinical, pharmacokinetic and biomarker data become available

• Work directly with investigators and study teams on patient eligibility, safety events and clinical questions that arise during treatment

• Partner with Clinical Operations, Translational Sciences and Regulatory Affairs to deliver studies and translate emerging evidence into programme decisions

• Lead investigator meetings and advisory boards, and represent the organisation in discussions with key opinion leaders and external partners

• Bring current oncology practice into development planning, including evolving standards of care, treatment sequencing and how new therapies could fit into the patient pathway

Candidate profile

• Medical degree and specialist qualification in Medical Oncology, essential

• At least 4 years of experience in pharma or biotech, with substantial involvement in Phase 1 oncology development and experience in Phase 2

• A track record of shaping clinical development plans and taking studies from protocol design through execution

• Experience designing dose escalation and expansion studies and using emerging data to guide dose, cohort and indication decisions

• Direct involvement in the medical oversight of active oncology trials, including patient-level data review and discussion of individual cases with investigators

• A strong grounding in solid tumour clinical practice and patient management

• Experience developing small molecule oncology assets is highly desirable

Why consider it

You’ll have the scope to shape how new compounds enter the clinic while staying directly involved in the studies that determine their future. With several assets at different stages, you could be designing the first clinical study for one compound, interpreting expansion cohort data for another and helping a more advanced programme prepare for its next phase.